future health glp 1 GLP-1 PROTEIN + Future Nutrition's GLP-1 user-targeted GLP-1
Description
Globally, 90% of diabetes patients have TIIDM
It is a major therapeutic target for type 2 diabetes and obesity
The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatment of metabolic diseases, with the most recent glucose-dependent insulinotropic peptide receptor:glucagon-like peptide 1 receptor:glucagon receptor (GIPR:GLP-1R:GCGR) triagonists rivaling the efficacy of bariatric surgery
22, 2025 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not constitute medical advice
